



PRODUCT: **ENHERTU®**

COMPANY: Daiichi Sankyo & AstraZeneca

THERAPEUTIC AREA & INDICATION:
Treatment of unresectable or metastatic
HER2 positive breast cancer

ABOUT THE PRODUCT

ENHERTU® (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S.) is a HER2 directed antibody drug conjugate approved in the U.S. and Japan for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting based on the DESTINY-Breast01 trial. Daiichi Sankyo and AstraZeneca have a comprehensive development program underway globally with eight registrational trials evaluating the efficacy and safety of ENHERTU monotherapy across multiple HER2 cancers including breast, gastric and lung cancers. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.